AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23290065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation robot for lower-limb training (10-20 min/d, 6 d/week for 8 weeks)
Number of subjects: 48
Study 23290065 — intervention group
Group type: COMPARATOR
Intervention: Neuro-facilitation technique (control group)
Number of subjects: 48
Study 20378197 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine insulin therapy
Number of subjects: 138
Study 20378197 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin therapy
Number of subjects: 138
Study 17951477 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 730 mg/d for 28 d
Number of subjects: 41
Study 17951477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15079026 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms (NPI+)
Number of subjects: 1010
Study 15079026 — intervention group
Group type: COMPARATOR
Intervention: No neuropsychiatric symptoms (NPI-)
Number of subjects: 1010
Study 12572723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonized sunflower oil (Oleozon) applied twice per day for 6 weeks
Number of subjects: 200
Study 12572723 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole cream 2% (Nizoral) applied twice per day for 6 weeks
Number of subjects: 200
Study 9703599 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasonography of the parietal wall for the diagnosis of peritoneal adhesions
Number of subjects: 130
Study 9703599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous laparoscopic maneuvers
Number of subjects: 130
Study 8591497 — intervention group
Group type: EXPERIMENTAL
Intervention: ComputerLink (experimental group)
Number of subjects: 102
Study 8591497 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 2669667 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.6 g/d of omega-3 fatty acids
Number of subjects: 8
Study 2669667 — intervention group
Group type: COMPARATOR
Intervention: corn oil (5.4 g/d linoleic acid)
Number of subjects: 8
Study 579116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibric acid (1.5 g daily for 1 year)
Number of subjects: 20
Study 31610436 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM‐I interpretation training
Number of subjects: 89
Study 31610436 — intervention group
Group type: COMPARATOR
Intervention: Control CBM‐I training
Number of subjects: 89
Study 30520424 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day removal
Number of subjects: 230
Study 30520424 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous detachment
Number of subjects: 230
Study 30520424 — intervention group
Group type: COMPARATOR
Intervention: 7-day removal vs Spontaneous detachment
Number of subjects: 230
Study 28189191 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic, resistance, and inspiratory muscle training)
Number of subjects: 20
Study 28189191 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 20
Study 25801289 — intervention group
Group type: EXPERIMENTAL
Intervention: THC administration
Number of subjects: 20
Study 24225780 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20
Study 24225780 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 20
Study 22046718 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 460
Study 22046718 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater level of education
Number of subjects: 460
Study 22046718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic ethnicity
Number of subjects: 460
Study 22046718 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally active coping style
Number of subjects: 460
Study 22046718 — intervention group
Group type: EXPERIMENTAL
Intervention: General physical health
Number of subjects: 460
Study 22046718 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-related emotional health
Number of subjects: 460
Study 19246160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 25
Study 19246160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16822127 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally structured flicker in the gamma band
Number of subjects: 0
Study 16822127 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous priming of vertices corresponding to distinct Kanizsa-type rectangles
Number of subjects: 0
Study 12784346 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus standard therapy (ondansetron 32 mg IV and dexamethasone 20 mg on Day 1; dexamethasone 8 mg twice daily on Days 2-4)
Number of subjects: 523
Study 12784346 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ondansetron 32 mg IV and dexamethasone 20 mg on Day 1; dexamethasone 8 mg twice daily on Days 2-4)
Number of subjects: 523
Study 12784346 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus standard therapy
Number of subjects: 523
Study 12784346 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 523
Study 11006251 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide 1% in cyclodextrin solution
Number of subjects: 8
Study 11006251 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide (Trusopt)
Number of subjects: 8
Study 8835708 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (PAR), 20 mg/day
Number of subjects: 9
Study 8835708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mls of Iopamiro 370 at 2 mls/sec scanning inferosuperiorly
Number of subjects: 90
Study 1445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mls of Iopamiro 370 at 2 mls/sec scanning superoinferiorly
Number of subjects: 90
Study 1445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mls of Iopamiro 370 at 1 ml/sec scanning inferosuperiorly
Number of subjects: 90
Study 1445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mls of Iopamiro 370 at 1 ml/sec scanning inferosuperiorly
Number of subjects: 90
Study 1445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mls hand injected bolus followed by 60 ml pump infusion at 1.3 mls/sec scanning inferosuperiorly
Number of subjects: 90
Study 1445103 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mls hand injected bolus scanning inferosuperiorly
Number of subjects: 90
Study 2996575 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 13)
Number of subjects: 25
Study 2996575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 25
Study 31538907 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (2 capsules containing 500 mg of phosphatidylcholine complex of curcumin)
Number of subjects: 80
Study 31538907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two 500 mg placebo capsules)
Number of subjects: 80
Study 31538907 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation
Number of subjects: 80
Study 31538907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29248657 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac CT protocol
Number of subjects: 268
Study 27324599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual healthcare training programme (4 weeks, 16 hours)
Number of subjects: 117
Study 27324599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training programme)
Number of subjects: 117
Study 24440362 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral hip muscle strengthening
Number of subjects: 36
Study 24440362 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening
Number of subjects: 36
Study 23054866 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with additional trace elements for 28 days
Number of subjects: 18
Study 23054866 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) alone for 28 days
Number of subjects: 18
Study 20410232 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding (+50% calories)
Number of subjects: 46
Study 20410232 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 46
Study 19093919 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Management Plus (CMP) with nurse care managers supported by specialized information technology
Number of subjects: 3432
Study 19093919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3432
Study 15500091 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy (LG) with lymph node dissection
Number of subjects: 0
Study 15500091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 15500091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensitivity test-guided chemotherapy
Number of subjects: 0
Study 10917407 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-125 mg
Number of subjects: 8
Study 10917407 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine-40 mg
Number of subjects: 8
Study 10917407 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-125 mg and MDMA-75 mg
Number of subjects: 8
Study 10917407 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 8
Study 9207617 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade treatment
Number of subjects: 3039
Study 9207617 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3039
Study 9207617 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-carvedilol drugs
Number of subjects: 3039
Study 8365381 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of zinc as zinc sulphate
Number of subjects: 33
Study 8365381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3510848 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage oral metoclopramide (three times 50 mg) with prednisone (three times 25 mg)
Number of subjects: 58
Study 3510848 — intervention group
Group type: COMPARATOR
Intervention: High-dosage oral metoclopramide (three times 50 mg) without prednisone
Number of subjects: 58
Study 29742550 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker (Fitbit Zip) connected to an online lifestyle program
Number of subjects: 72
Study 29742550 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 72
Study 29742550 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (56%, increasing minimally 1000 steps/d)
Number of subjects: 72
Study 29742550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 72
Study 27479174 — intervention group
Group type: EXPERIMENTAL
Intervention: KI polyomavirus infection
Number of subjects: 1077
Study 27479174 — intervention group
Group type: EXPERIMENTAL
Intervention: WU polyomavirus infection
Number of subjects: 1077
Study 24907689 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ml of a mixed-nutrient drink (750kcal) 30 min prior to meal
Number of subjects: 16
Study 24907689 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ml of a mixed-nutrient drink (750kcal) 90 min prior to meal
Number of subjects: 16
Study 24907689 — intervention group
Group type: EXPERIMENTAL
Intervention: 500ml of a mixed-nutrient drink (750kcal) 180 min prior to meal
Number of subjects: 16
Study 24907689 — intervention group
Group type: COMPARATOR
Intervention: 500ml of water 180 min prior to meal (control)
Number of subjects: 16
Study 22549281 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition (ramipril 5 mg/day)
Number of subjects: 0
Study 22549281 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (candesartan 16 mg/day)
Number of subjects: 0
Study 22549281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19513578 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty (5.56 +/- 0.62 mL of PMMA)
Number of subjects: 100
Study 19513578 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty (4.91 +/- 0.65 mL of PMMA)
Number of subjects: 100
Study 18392240 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial walking (4 km/h)
Number of subjects: 10
Study 18392240 — intervention group
Group type: COMPARATOR
Intervention: Postprandial consumption of alcoholic digestifs (brandy, herb flavored liqueur, Williams pear brandy, aquavit, espresso)
Number of subjects: 10
Study 16153933 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (0.05 micro/kg/h) for 72 hours after cardiopulmonary bypass
Number of subjects: 42
Study 16153933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12942852 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Lutéran tablet
Number of subjects: 12
Study 12942852 — intervention group
Group type: COMPARATOR
Intervention: 5 mg Lutéran tablets (control)
Number of subjects: 12
Study 10397377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg
Number of subjects: 23
Study 10397377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 800 mg
Number of subjects: 23
Study 10397377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 1200 mg
Number of subjects: 23
Study 10397377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 1600 mg
Number of subjects: 23
Study 10397377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8889461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 15
Study 8889461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 80 mg
Number of subjects: 15
Study 8889461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 120 mg
Number of subjects: 15
Study 8889461 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 15
Study 1996921 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline hydrobromide (1.0 mg)
Number of subjects: 0
Study 1996921 — intervention group
Group type: COMPARATOR
Intervention: Arecoline hydrobromide (0.5 mg)
Number of subjects: 0
Study 1996921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6508224 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 49
Study 6508224 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia
Number of subjects: 49
Study 6508224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 49
Study 6508224 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia without volatile agent
Number of subjects: 49
Study 6508224 — intervention group
Group type: COMPARATOR
Intervention: Postoperative T-tube group (Control)
Number of subjects: 49
Study 6508224 — intervention group
Group type: EXPERIMENTAL
Intervention: All anaesthetized groups
Number of subjects: 49
Study 31159793 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Learning resources (Group A)
Number of subjects: 19
Study 31159793 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 19
Study 31159793 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-test questionnaire on e-Learning resources
Number of subjects: 19
Study 29523557 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (including stent retriever thrombectomy, aspiration, and alternative methods)
Number of subjects: 1488
Study 29523557 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 1488
Study 28157671 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat germ-enriched bread (6 g of wheat germ)
Number of subjects: 55
Study 28157671 — intervention group
Group type: COMPARATOR
Intervention: Non-enriched bread (control)
Number of subjects: 55
Study 23952739 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel applied twice a day after stitches removal
Number of subjects: 26
Study 23952739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin cream applied twice a day after stitches removal
Number of subjects: 26
Study 23952739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study 22610181 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mean daily fluid balance
Number of subjects: 1453
Study 19092551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-case-managed sessions plus targeted hepatitis education, incentives, and tracking (NCMIT)
Number of subjects: 865
Study 19092551 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted hepatitis education plus incentives and tracking (SIT)
Number of subjects: 865
Study 19092551 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted hepatitis education and incentives only (SI)
Number of subjects: 865
Study 17319887 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information about communicating with family and basic organ donation information
Number of subjects: 109
Study 17319887 — intervention group
Group type: COMPARATOR
Intervention: Basic organ donation information only
Number of subjects: 109
Study 15207898 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg per day)
Number of subjects: 70
Study 15207898 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg per day)
Number of subjects: 70
Study 15207898 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 70
Study 15207898 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (1 year after cessation of anti-estrogen)
Number of subjects: 70
Study 11306202 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens at 0.625 mg/d plus trimonthly medroxyprogesterone acetate at 5 mg/d for 13 days (HRT)
Number of subjects: 52
Study 11306202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 9141148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously injected human corticotropin releasing factor (hCRF)
Number of subjects: 21
Study 9141148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 5-minute stress test
Number of subjects: 21
Study 9141148 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy young men)
Number of subjects: 21
Study 9141148 — intervention group
Group type: COMPARATOR
Intervention: Older healthy subjects and alcoholics
Number of subjects: 21
Study 10137793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drug coverage for new enrollees
Number of subjects: 0
Study 10137793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cost drugs
Number of subjects: 0
Study 10137793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low users of prescription drugs
Number of subjects: 0
Study 10137793 — intervention group
Group type: COMPARATOR
Intervention: Established enrollees
Number of subjects: 0
Study 3312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 50
Study 3312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus tobramycin
Number of subjects: 50
Study 3312032 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin plus tobramycin
Number of subjects: 50
Study 28816072 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Number of subjects: 7
Study 28816072 — intervention group
Group type: COMPARATOR
Intervention: Electrochemotherapy (bleomycin)
Number of subjects: 7
Study 27317971 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories, Sodium, + Contextual Statement (CS) menu
Number of subjects: 0
Study 27317971 — intervention group
Group type: EXPERIMENTAL
Intervention: Calories + Contextual Statement (CS) menu
Number of subjects: 0
Study 27317971 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions providing sodium information
Number of subjects: 0
Study 27317971 — intervention group
Group type: COMPARATOR
Intervention: No Nutrition Information, Calories‐Only, Calories + CS, Calories, Sodium, + CS, Calorie and Sodium in Traffic Lights + CS
Number of subjects: 0
Study 25264047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mekabu (70 g) with a white rice-based breakfast
Number of subjects: 0
Study 25264047 — intervention group
Group type: COMPARATOR
Intervention: Wakame with a white rice-based breakfast
Number of subjects: 0
Study 25264047 — intervention group
Group type: COMPARATOR
Intervention: Control meal (without Mekabu or Wakame)
Number of subjects: 0
Study 21814218 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet (D)
Number of subjects: 30
Study 21814218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 30
Study 21814218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of D+EX
Number of subjects: 30
Study 21814218 — intervention group
Group type: COMPARATOR
Intervention: D alone
Number of subjects: 30
Study 21814218 — intervention group
Group type: COMPARATOR
Intervention: EX alone
Number of subjects: 30
Study 20819421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture 0.76 g/day
Number of subjects: 41
Study 20819421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture 1.52 g/day
Number of subjects: 41
Study 20819421 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture 1.52 g/day coadministered with conjugated linoleic acid 1.6 g/day
Number of subjects: 41
Study 20819421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 18417744 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (50% dose increase at randomization)
Number of subjects: 321
Study 15629985 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation (pleasant odor diffused during 24 hours in the incubator)
Number of subjects: 14
Study 12591556 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded formulated complementary diet from maize and cowpea (L(1)A(1))
Number of subjects: 30
Study 12591556 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-average socioeconomic background (HN)
Number of subjects: 30
Study 12591556 — intervention group
Group type: COMPARATOR
Intervention: Control group (L(2)N)
Number of subjects: 30
Study 12711184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the stomach
Number of subjects: 9
Study 12711184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the proximal small bowel
Number of subjects: 9